

Name (Print):

Date/Time:

Tentamus California Sample Submission Form

Attention: Sample Receiving Department

133 Technology Drive, Suite 150, Irvine, CA 92618

PLEASE READ THESE INSTRUCTIONS BEFORE FILLING OUT THIS FORM AND SHIPPING SAMPLES

1. Please contact TentamusCalifornia for all RUSH pre-approval at 858.750.2146

2. If your samples exceed available space, please attach additional sample submission forms.

3. For **Pharmaceutical Samples** please include the company FEI number.

a. If a verification is not on file for your finished product API testing, Fill Out Page 2

Doc ID: 7475 Revision: 5

Issue Date: 10/7/2025

Contact Information						for th	e test method releas	e.					
Company:					Invoice Conta	act:				Date:			
Contact Name:					Billing Addre	ess:							
Mailing Address:					(if different)			1			er:		
Email (reports):					FDA FEI# (phs	.,				Product Ty	Pharma/GMP/ Natural Health Other:		
Identity: HPTLC/Micr	oscony	Tost Ra	panest(s)		Eman (invoic	es).			_				
Lot#	Sample	Name /De			Latin Name (Genus/Species)		Plant Part	Extraction Solver (if known)		TAT	Laboratory Use Or	dy	
Analytical: Microbiolo	gy/HPI	.C/GC/	UV-vis/Chemistry Test Requ	iest(s)			•	•		•			
Lot#	Sample Name /Description		Assay/Marker (Test For)			Specification (If Required)			TAT	Laboratory Use On	aboratory Use Only		
			er sample and correctly executed and signed samp around time is based on industry accepted method										
		Sample Disposal		Data to be	Data to be used for		_	Special Instructions/Request					
STD - Standard - 7 Business Days 5D - 5 BUSINESS DAYS - +20% 4D - 4 BUSINESS DAYS - +25% 3D - 3 BUSINESS DAYS - + 50% 2D - 2 BUSINESS DAYS - + 100% 1D - 1 BUSINESS DAYS - + 100% SAME DAY RUSH - +400%		☐ Standard Disposal ☐ Return (cost of sample shipping per sample) ☐ Retain for 3 month period (\$50)		Regu	Regulatory Submission to FDA		Instructions or	Check here if sample(s) require special storage conditions or handling precautions. Explain in the Special Instructions or Request.: It is recommended that suitability testing be performed on formulas being tested for microbiology per USP <51>, <60>, <61>, and <62>. Please denote if your are opting out: Yes, I am opting out					
All RUSHES MUST BE APPROVED		* Standard Disposal if nothing is selected			selected, results will be reported for only and considered non-pharma work.								
Laboratory Use			All fees or bills are charged directly to you, the describes the testing desired. If changes are mann in signing below, the Client accepts the above to	de after the origin	nally requested testin								
Received By:					ponsioninos.								

Client Approval:

Date:



Method Acceptance Release Form

Doc ID: 16888 Revision: 3

Issue Date: 10/7/2025

This informed consent/assumption of risk/waiver/release of liability pertains to the method summarized below. A detailed description may be attached to this document. Method/Analyte To Be Tested:

, (Client). I a	(Full Name of Client's Representative), certify that I am an authorized representative of
	California (hereinafter "TCA") cannot perform the requested testing services without obtaining signed written permission, informed consent, ght to sue, and a release of liability.
	The undersigned knowingly and voluntarily accepts that the method as currently constituted may not be fully validated prior to usage by California.
perform va	TCA does not possess proof of method suitability for this method. TCA will at their discretion, or through joint collaboration with the Client, lidation work to determine method suitability. If and when this validation is completed the validated method will be used in lieu of this method erwise requested, in writing, from the Client.
	TCA is committed to achieving the highest client satisfaction professionally and ethically; and agrees to perform the prescribed method to stated procedures. However, TCA makes no claims as to the precision, accuracy, or suitability of such method.
acceptanc	TCA, its Clients, and its employees are discharged, released, and absolved from any and all claims and liabilities associated with the e and usage of this method, INFORMED CONSENT/ASSUMPTION OF RISK/WAIVER/RELEASE OF LIABILITY for the testing services that have not been properly validated by TCA's research team, if said method is later determined to be unsuitable for the test requested.
By signing t consent, as any right we	TCA agrees to undertake remediation, corrective action, and retest, if the prescribed method is erroneously implemented. sis form, we give written permission to TCA to use the prescribed method without validation by TCA. We acknowledge that we have thoroughly read this informed sumption of risk, waiver of right to sue, and release of liability and fully accept and assume any and all risks and liability herein. We knowingly and voluntarily waive, or our successors, might have to bring any legal action or assert any claims, demands, or causes of action of any kind whatsoever against TCA, its Clients, and is, for any issues associated with the proper execution of prescribed unvalidated method used for the requested testing services defined by this document.
	istration FEI #:
DUNS #:	
Dated: _	(mm/dd/yyyy)
Signature	of Authorized Representative:
Name of	Authorized Representative:
Client/Co	mpany:
Addendı	m I: Products Released for Test Method

Method Acceptance Release Tests							
Method/Test Analyte Name	Product Name	Active Pharmaceutical Ingredient	Client Product Code				

Revision: 3

Issue Date: 10/7/2025